Clarity Pharmaceuticals Ltd

Other

Isis Innovation Limited

Paul Stephen Donnelly

Nicholas Alan Zia

Kevin Jeffrey Barnham

Michelle Therese Ma

Jonathan Dilworth

Brett Paterson

Anthony R White

Josephine Mary Peach

Julia May Heslop

Denis Bernard Scanlon

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Radiopharmaceuticals, radioimaging agents, and uses thereof

The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.

Targeting compounds and methods for their production

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterized by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

Metal delivery agents and therapeutic uses of the same

A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X', Y, L1&#x2032;, R1&#x2032; and R2&#x2032; are as defined herein, is useful in medical imaging and therapy.

Growing community of inventors

Melbourne, Australia

Paul Stephen Donnelly